I build financial models and write investment analysis on public companies and transactions — take-privates, buy-side M&A, contrarian equity situations. Every model is built to institutional standards and audited before it is published.
Each analysis includes a written memo and the underlying Excel model. All figures are sourced from public filings.
A full bank three-statement model: interest income as the top line, provisions as the major operating expense, and distributions capped by the CET1 ratio rather than by cash. The finding is that the Greek bank discount has largely closed — and what remains is a view on how little Greek depositors demand to be paid. 947 formulas, historicals tie to reported on every line.
A full independent-sponsor buyout model on a debt-free footwear platform: senior debt + seller note, DSCR covenant, cash sweep, and an 8% pref + tiered promote waterfall. 3.9x / 30% gross with zero multiple expansion — every tie verified on a passing audit tab.
Full PE take-private analysis of a £9.4bn deal. DCF, LBO, Sum-of-Parts and Comps models. Why EQT's £60/share was right — and where the returns actually come from.
Full equity analysis of a €6.6bn market cap at 5.3x EV/EBITA. AI Scenario Analysis, DCF, LBO, and Comps. Why the Kodak analogy is wrong — and what the current price implies.
PE exit analysis on a German defence manufacturer with a €15bn+ order backlog. Did Triton leave money on the table? DCF, LBO reconstruction, and backlog-driven valuation.
A buy-side valuation, synergy and deal-returns assessment of the £9.9bn cash acquisition that ends 222 years of family ownership at one of the City's oldest names. Is the price fair?
Is the market mispricing a structural winner? Full investment analysis on Demant — aging demographics, hearing aid penetration, competitive dynamics, and a DCF that challenges the current valuation.
Europe's largest bank trading at a 32% discount to book. Full investment analysis on BNP Paribas — capital strength, AXA IM integration, rate sensitivity, and a valuation case for re-rating.
A 50% drawdown from peak, a pipeline in flux, and a market still pricing in peak GLP-1 dominance. Full investment analysis on Novo Nordisk — competitive moat, CagriSema data, pipeline optionality, and a valuation case for recovery.
Financial model templates, built to institutional standards and free to download. Unlocked and documented.
I am a final-year economics student at the National and Kapodistrian University of Athens. My work sits at the intersection of equity research, M&A and private equity — the analysis that sits underneath an investment decision rather than the commentary that follows it.
I hold the FMVA certification from the Corporate Finance Institute, the CFA Institute's Private Markets and Alternative Investments Certificate, and completed Yale's Financial Markets programme. I am currently enrolled in the Oxford Private Markets Investments Programme and the AI & Machine Learning Specialist in Financial Services Programme by the National and Kapodistrian University of Athens. Everything published here is produced independently, from public filings, and is intended as a demonstration of method as much as conclusion.
For research enquiries, corrections, or to discuss any of the analysis published here.